Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

BigBear.ai Shares Plummet Following Disastrous Quarterly Report

Robert Sasse by Robert Sasse
September 11, 2025
in AI & Quantum Computing, Earnings, Tech & Software
0
BigBear.ai Stock
0
SHARES
177
VIEWS
Share on FacebookShare on Twitter

BigBear.ai shares are experiencing a severe and sustained sell-off, with multiple consecutive days of losses highlighting a dramatic shift in investor sentiment. The catalyst for this downturn was the release of a quarterly earnings report that fell catastrophically short of expectations, raising fundamental concerns about the company’s future trajectory.

Earnings Shock and Revenue Shortfall

The company’s second-quarter performance delivered a profound shock to the market. BigBear.ai reported a loss of $0.71 per share, a figure that vastly exceeded the $0.06 per share loss anticipated by analysts. The revenue picture proved equally troubling, with the company generating $32.5 million against a consensus forecast of approximately $41 million. This result also represents a significant 18.3% decline compared to the same period last year.

Slashed Guidance Erodes Investor Confidence

Compounding the poor quarterly results, management executed a drastic reduction in its full-year outlook. The revenue forecast was slashed from an initial range of $160-$180 million down to just $125-$140 million. Company leadership attributed this downward revision primarily to unexpected delays in securing contracts with U.S. government agencies. In a further blow to confidence, the company completely withdrew its EBITDA guidance for the year.

Should investors sell immediately? Or is it worth buying BigBear.ai?

A Multitude of Pressures Weighs on the Stock

Investors are grappling with several concurrent negative developments:

  • Massive Earnings Miss: Quarterly results fell far short of Wall Street projections on both profit and revenue metrics.
  • Drastically Revised Outlook: The severe cut to the annual revenue forecast, blamed on government contract delays, has shattered forward-looking confidence.
  • Threat of Share Dilution: The company filed paperwork for the potential sale of up to 65 million new common shares, a move that would significantly dilute the ownership of existing stockholders.
  • Pessimistic Signals: Recent insider stock sales in the absence of any purchases have added to the overwhelmingly negative market sentiment.

Assessing the Financial Foundation

The company’s current valuation metrics paint a concerning picture of its financial health. BigBear.ai’s price-to-book ratio sits substantially higher than the industry median. More alarmingly, its Altman Z-Score has moved into the distress zone, a recognized indicator signaling a tangible risk of bankruptcy within the next two years. These factors collectively reinforce the powerful downward trend currently gripping the stock.

Ad

BigBear.ai Stock: Buy or Sell?! New BigBear.ai Analysis from February 8 delivers the answer:

The latest BigBear.ai figures speak for themselves: Urgent action needed for BigBear.ai investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

BigBear.ai: Buy or sell? Read more here...

Tags: BigBear.ai
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
AvidXchange Holdings Stock

Countdown to Acquisition: AvidXchange Nears Privatization Milestone

Zurn Water Solutions Stock

Zurn Water Solutions Stock Reaches Unprecedented Peak

Red Cat Stock

Red Cat Stock Plummets Despite Major Defense Sector Expansion

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com